

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of active RSK1 [1 - 735]**

<b><u>Enzyme description:-</u></b>	RSK1 [1 - 735]
<b><u>Clone number:-</u></b>	DU 687
<b><u>Source:-</u></b>	Recombinant
<b><u>Expression system:-</u></b>	Baculovirus expression vector system
<b><u>Tag:-</u></b>	N-terminal His(6) and HA
<b><u>Purification method:-</u></b>	Ni <sup>2+</sup> -NTA agarose
<b><u>Expression level:-</u></b>	3-5 mg/L
<b><u>Calculated molecular mass:-</u></b>	88, 284 daltons
<b><u>Purity:-</u></b>	>85 %

#### **Activation protocol:-**

RSK1 (2  $\mu$ M) is activated by incubation with 5 U/ml GST-p42MAPKinase [DU 650 or DU1844] and 1 U/ml GST-PDK1 [DU 954] in 50mM Tris-HCl pH 7.5, 0.1mM EGTA, 0.1 % 2-mercaptoethanol, 10 mM magnesium acetate, 0.1 mM ATP for 30 min at 30 °C. Following activation, the active RSK1 is repurified by Ni<sup>2+</sup>-NTA agarose chromatography.

#### **Enzyme storage buffer:-**

50 mM Tris-HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1mM EGTA, 0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF.

**Storage temperature:-** -70 °C

**Assay:-** Standard filter binding assay

#### **Assay buffer:-**

50 mM Tris-HCl pH 7.5, 0.1 % 2-mercaptoethanol, 0.1 mM EGTA, 10 mM MgAc

*Division of Signal Transduction Therapy*

**Substrate:-**

Long S6 [KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK]

Final concentration: 30  $\mu$ M

**Specific activity range:-** 300 – 600 U/mg

# Division of Signal Transduction Therapy

## Clone Data Sheet

### RSK1 [1 - 735]

<b><u>Protein</u></b>	RSK1 [1 - 735]
<b><u>Clone number</u></b>	DU 687
<b><u>Species</u></b>	Rat
<b><u>Accession number</u></b>	M99169
<b><u>Tags</u></b>	N-terminal His(6) and HA (YPYDVPDYA)
<b><u>Baculovirus expressed protein</u></b>	<p>MSYYHHHHHHHDYDIPTTENLYFQGGAMDPEFAAATMYPYDVPDYALEMPL AQLKEPWPLMELVPLDPENGOASGEEAGLQPSKDEGILKEISITHHVKA GSEKADPSHFELLKVLGQGSFGKVFLVRKVTRPDNGHLYAMKVLKKATL KVRDRVRTKMERDILADVNHFPVVKLHYAFQTEGKLYLILDFLRGGDLF TRLSKEVMFTEEDVKFYLAELALGLDHLHSLGIIYRDLKPENILLDEEG HIKLTDFGLSKEAIDHEKKAYSFCGTVEYMAPEVVNRQGHTHSADWWSY GVLMEMLTGSLPFQGKDRKETMTLILKAKLGMPQFLSTEAQSLLRALF KRNPANRLGSGPDGAEEIKRHIFYSTIDWNKLYRREIKPPFKPAVAQPD DTFYFDTEFTSRTPRDSPIPPSAGAHQLFRGFSFVATGLMEDDSKPRA TQAPLHSVQQLHGKNLVFSDGYIVKETIGVGSYSVCKRRCVHKATNMEY AVKVIDKSKRDPSEEIEILLRYGQHPNIIITLKD VYDDSKHVYLVTELMR GGELLDKILRQKFFSEREASFVLYTISKTV EYLHSQGVVHRDLKPSNIL YVDESGNPGCLRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGY DEGCDIWSLGVLLYTMLAGYTPFANGPSDTP E EILTRISSGKFTLNGGN WNTVSETAKDLVSKMLHVDPHQRLTAKQVLQHPWITQKDKLPQSLSHQ DLQLVKGAMAATYSALSSSKPTPQLKPIESSILAQRRVRKLPSTTL</p>
<b><u>Native sequence</u></b>	<p>Amino acids M1 – L735 (end) of rat RSK1. Residue M47 of the fusion protein is equivalent to M1 of the native enzyme. The His(6) tag is located at residues 5 – 10 and the HA tag is located at residues 36 – 44.</p> <p>The following amino acid substitutions are present: E – G, where E551 of the native sequence is G597 of the fusion protein. S – N, where S637 of the native sequence is N683 of the fusion protein. G – A, where G697 of the native sequence is A743 of the fusion protein. The additional glutamine, Q157 (native sequence) reported in Dalby <i>et al.</i> (1998) <i>J.Biol.Chem.</i> <b>273</b>, 1496-1998, has been removed from the fusion protein.</p>

## *Division of Signal Transduction Therapy*

**Protease cleavage**     rTEV (ENLYFQG) residues 18 - 24

**Cloning sites**         *Not1* site in pFastBAC HTb

## *Division of Signal Transduction Therapy*

### **Complete nucleotide sequence**

ATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCAACGA  
CCGAAAACCTGTATTTTCAGGGCGCCATGGATCCGGAATTCGCGGCCGC  
CACCATGTACCCATACGATGTTCCAGATTACGCTCTCGAGATGCCGCTC  
GCCAGCTCAAGGAACCTTGGCCGCTCATGGAGCTGGTGCCGCTGGACC  
CGGAGAATGGACAGGCTTCAGGGGAAGAAGCTGGACTTCAGCCATCCAA  
GGATGAGGGCATCCTCAAGGAGATCTCTATCACACACCACGTCAAGGCT  
GGCTCTGAGAAGGCTGATCCATCCCATTTTGAGCTCCTCAAGGTTCTGG  
GCCAAGGATCCTTTGGCAAAGTCTTCTGGTACGCAAGGTCACCCGGCC  
TGACAATGGGCACTTGTATGCCATGAAAGTATTAAGAAGGCCACGCTG  
AAAGTGCGTGACCGTGTTCGGACCAAGATGGAGAGAGACATCCTAGCTG  
ACGTGAACCACCCCTTCGTAGTGAAGTGCCTATGCCTTCCAGACCGA  
GGCAAGCTCTATCTTATTCTGGACTTTCTGCGTGGTGGAGACCTGTTC  
ACACGACTCTCAAAGGAGTTATGTTTACAGAGGAGGATGTGAAGTTTT  
ACCTGGCTGAGCTGGCACTGGGCCTGGACCACCTGCACAGCTTGGGCAT  
CATTTACAGAGACCTCAAGCCTGAAAATATCCTTTTGGATGAGGAGGGC  
CACATCAAACCTCACTGACTTTGGCCTGAGCAAGGAGGCCATTGACCACG  
AAAAGAAGGCCTATTCCTTCTGCGGGACGGTGGAGTACATGGCCCCCGA  
GGTTGTCAACCGCCAGGGCCACACCCACAGTGCAGATTGGTGGTCTCTAT  
GGGTGTTGATGTTTGAAGTGTGACGGGCTCCCTGCCCTTCCAGGGGA  
AGGACCGGAAGGAGACCATGACCTTGATTTTGAAGGCAAAGCTAGGCAT  
GCCCCAGTTTCTGAGCACGGAAGCCAGAGCCTCCTGCGGGCCCTGTTC  
AAGAGGAATCCTGCCAACCGGCTTGGCTCAGGCCCCGATGGGGCTGAGG  
AAATTAAGAGACATATCTTCTACTCTACCATTGACTGGAATAAGCTCTA  
CCGCCGTGAGATCAAGCCACCTTTCAAGCCCGCTGTGGCCCAACCGGAT  
GACACCTTCTACTTTGATACCGAGTTCACGTCACGCACACCCAGGGATT  
CGCCGGGCATCCCCCCCAGTGTGGTGCCATCAGCTCTTCCGTGGCTT  
CAGCTTCTGTGGCCACCGGTCTGATGGAGGATGACAGCAAGCCTCGGGCC  
ACCCAAGCTCCGCTGCACTCGGTGGTACAGCAACTCCACGGGAAGA  
TGGTTTTTCAGCGATGGCTACATAGTAAAGGAGACGATCGGCGTGGGCTC  
CTACTCTGTGTGTAAGCGTGTGTCCACAAGGCCACCAACATGGAGTAC  
GCAGTCAAAGTCATCGACAAAAGCAAAGAGATCCCTCCGAAGAGATCG  
AGATTCTTCTGCGGTATGGACAGCACCCCAACATCATCACCCCTGAAAGA  
TGTGTATGACGACAGTAAGCACGTATACTGGTGACAGAGTTGATGAGG  
GGCGGGGAGCTGCTGGATAAGATCCTACGGCAGAAATCTTCTCAGAGC  
GGGAGGCCAGCTTCGTCTGTACACCATCAGCAAGACTGTGGAATACTT  
GCAC'TCCCAAGGGGTCTGTCACAGGGACCTCAAACCCAGTAACATCCTG  
TATGTGGATGAGTCTGGGAACCCCGGATGCCTACGAATATGCGACTTTG  
GCTTTGCCAAGCAGCTACGGGCTGAGAACGGGCTTCTCATGACACCTTG  
CTACACAGCCAACTTTGTGGCACCTGAGGTGCTGAAGCGTCAGGGCTAC  
GATGAAGGCTGTGACATATGGAGCCTGGGCGTTCTGCTGTACACGATGC  
TGGCAGGATACACTCCATTTGCCAATGGGCCAGTGATAACCCAGAGGA  
GATCCTCACCCGGATCAGCAGTGGGAAGTTACCCTCAACGGGGGAAAC  
TGGAACACGGTTTCAGAGACAGCCAAGGACTTAGTATCTAAGATGCTGC  
ATGTGGACCCCCACCAGCGCCTCACAGCCAAACAGGTTCTGCAGCACC  
GTGGATCACCCAGAAAGACAAGCTCCCCCAGAGCCAGTTGTCCCACCAA  
GACCTGCAGCTTGTGAAGGGGGCCATGGCAGCTACATATTCTGCACTCA  
GTAGCTCCAAACCCACCCCCAGCTCAAGCCAATCGAGTCTGTCATCCT  
GGCCAGCGGCGGGTGAGGAAGCTGCCATCCACCACCCTG

*Division of Signal Transduction Therapy*